De-risk your projects. Advance your therapeutics pipeline.
Providing expert consulting towards developing vaccines and immunotherapies – through project design and assay development to complex immune data analysis for clear, actionable insights.
Save time, reduce risk, and accelerate your therapeutic success.
Overview
Immunotherapy is at the forefront of therapeutic development, rapidly leading the fields of oncology, infectious disease, autoimmune disease, allergy & transplantation, and vaccine research. The demand for expertise in immunology has surged, with sectors changing strategy to encompass new technologies and discoveries. However, supply of the required expertise is lacking, with significant resources required for in-house investment.
At Kelpie Immunology, we support biotech and pharmaceutical companies to develop their innovative projects through driving project strategy, niche explorations, novel assay designs, and data analysis and presentation. This culminates in a solid project while directly relating into translational results, de-risking your projects, and reducing resource investment.
Our Services
Strategic insight & project exploration
• Review current project data, goals, and development.
• Identify weak points and missed potentials.
• Integrate forefront, targeted assays.
• De-risk.
Assay design & development
• Novel assay design and optimisation based on project needs.
• Bench guidance towards increasing data value and quality.
Data analyis & interpretation
• Statistical analysis and interpretation.
• Recommend experimental direction.
• Translate data into practical relevance.
Scientific writing & communication
• Compelling summaries for research teams and investors.
• Contribution to manuscripts, presentations, and grant applications.
• Presentation-ready figures and reports.
Suitable Projects
Immuno-oncology
Novel cancer immunotherapies and functional immune assays.
Vaccines & infectious diseases
Antimicrobials, antivirals, antifungals and vaccine development.
allergy & transplant
Immune tolerance, desensitization, and transplant rejection.
Autoimmune diseases
Therapeutics targeting immune dysregulation.
Dr. Mark McNeil
Dr. Mark McNeil is an immunologist with over a decade of experience spanning academic research and the pharmaceutical industry involving virology, microbiology, autoimmune diseases and cancer research. He has advanced assay development, data interpretation and scientific communications in projects ranging from early-stage target discovery to the development of therapeutics. Mark founded Kelpie Immunology after identifying a demand for immunological expertise without the resource strain of operating in-house. Mark’s aim is to guide teams through the complexities of immune-based R&D faster and more efficiently with the goal of developing new therapeutics.
Prior Projects
A global pharmaceuticals company developing innovative oncology therapeutics through immunce cell manipulation required substantial cell-based therapeutics validation. A lead compound was identified using high-throughput cell, protein and gene expression multi-plex assays and proved to be significantly better than current standards available.
A leading academic group at the UK’s No 1 university were investigating unknown mechanisms employed by a viral pathogen to hijack and manipulate host cells. Novel cell-based assays were designed involving pathogenic infections and gene modification and resulted in the discovery of a key viral protein and it’s function, leading the way for a potential new anti-viral therapeutic and pushing understanding of virus-host interaction.
A global pharmaceutical company had developed new therapeutics for degrading targeted proteins but required it to undergo pre-clinical testing. Advanced methods were employed to replace ‘gold-standard’ assays and resulted in a lead compound being identified, opening the way for a new type of therapeutic mechanism.
A new academic group required novel assays to identify and track potential biomarkers of pain and disease. Using cutting-edge technology and new applications, an extensive range of excreted cellular proteins from historical and current samples were analysed leading to the identification of new biomarkers with the potential for use in diagnostics.
An academic group at a world-renowned university were monitoring current and historical pathogen emergence patterns to determine the effect of serotype specific vaccines. High-throughput methods were identified and employed and showed a significant need for a vaccine capable of cross-reacting with various pathogen serotypes to prevent niche variants emerging.
A leading global provider of clinical research services required a novel approach for designing a vaccine identified by the WHO as urgently needed. Several vaccine candidates were identified by designing and optimising a new assay capable of directly measuring pathogen elimination by immune cells as a result of vaccination. The developed assay outperformed the ‘gold-standard’ assay as used for decades.